Selumetinib
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Selumetinib
- Selumetinib: From NF1-Related Plexiform Neurofibroma to Familial Generalized Lentiginosis
Selumetinib: From NF1-Related Plexiform Neurofibroma to Familial Generalized Lentiginosis
One-Sentence Summary
Selumetinib is a MEK1/2 inhibitor whose established use is in neurofibromatosis type 1 (NF1)-related plexiform neurofibromas, acting by blocking the RAS-MAPK signaling pathway. The TxGNN model predicts it may be effective for Familial Generalized Lentiginosis, but this specific prediction is currently supported by 0 clinical trials and 0 publications — it is an AI-inference-only candidate with no direct evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | NF1-related plexiform neurofibroma (referenced in the drug’s own repurposing rationale; not formally recorded as a local marketing authorization) |
| Predicted New Indication | Familial generalized lentiginosis |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 |
| EU Market Status | Not marketed (Not marketed) |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from DrugBank for this evidence pack (High-severity data gap, DG002). Based on the information embedded in the evidence itself, Selumetinib is consistently described across multiple predicted-indication rationales as a MEK1/2 inhibitor that blocks the downstream RAS-MAPK signaling pathway — the same pathway already targeted in its known use for NF1-related plexiform neurofibromas.
Familial generalized lentiginosis sits within the broader RASopathy spectrum: related conditions such as LEOPARD syndrome / Noonan syndrome with multiple lentigines are caused by germline mutations in RAS-MAPK pathway genes (PTPN11, RAF1, BRAF). This creates a plausible, but indirect, mechanistic bridge between an MEK inhibitor and a lentiginosis phenotype.
However, the evidence pack’s own rationale explicitly flags this link as “僅為 TxGNN embedding 推論，無實際機轉驗證資料” (an embedding-similarity inference only, without any actual mechanistic validation). No preclinical or clinical data connect selumetinib specifically to familial generalized lentiginosis — the prediction should be treated as a hypothesis-generating signal, not a validated pharmacological rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
EU Market Information
This drug currently has no marketing authorization on record in this evidence pack (market status: Not marketed / Not marketed; total licenses: 0).
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (MEK1/2 inhibitor; non-cytotoxic mechanism) |
| Myelosuppression Risk | Please refer to the SmPC warnings and precautions |
| Emetogenicity Classification | Please refer to the SmPC warnings and precautions |
| Monitoring Items | Please refer to the SmPC warnings and precautions |
| Handling Protection | Please refer to the SmPC warnings and precautions |
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked prediction (familial generalized lentiginosis, TxGNN score 99.96%) has zero supporting clinical trials or literature — it is an L5, decision-stage S0 candidate based purely on knowledge-graph embedding similarity, with no mechanistic validation.
- Two Blocking/High-severity data gaps (label warnings/contraindications, and mechanism of action) currently prevent any safety pre-assessment (S1) for this drug in general.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain official product label warnings/contraindications before any S1 safety screening.
- Resolve DG002 (High): obtain formal DrugBank/SmPC mechanism-of-action data to properly assess mechanistic relevance.
- Generate at least preclinical mechanistic evidence directly linking selumetinib to familial generalized lentiginosis before advancing past S0.
- Note for portfolio consideration: within this same prediction set, peripheral nerve schwannoma (rank 9, L2, decision-stage S2) is supported by a selumetinib-specific NF2 Phase 2 trial (NCT03095248) and 7 relevant publications, and shares the same NF2/merlin–MAPK mechanistic logic as the drug’s established NF1 indication. This is a substantially stronger repurposing candidate and may warrant prioritized evaluation over the rank-1 prediction discussed here.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.